May 12, 2022 / 06:20PM GMT
Pavan R. Patel - BofA Securities, Research Division - Research Analyst
Good morning, and welcome to the morning session of Day 3 of the Bank of America Healthcare Conference. My name is Pavan Patel, and I'm one of the biotech analysts here at BofA. It's my pleasure today to introduce Arnon Rosenthal, Co-Founder, CEO and Director of Alector. Arnon, would you like to start off with some opening remarks? And then we could jump into Q&A.
Arnon Rosenthal - Alector, Inc. - Co-Founder, CEO & Director
Sure. Welcome, everyone. So as you know, the dominant therapeutic approach for dementia and neurodegeneration in the last 30 years was to target misfolded proteins. So every neurodegenerative disease is typified by its own misfolded protein. Alzheimer's is typified by A-beta and tau proteins. Parkinson's disease is typified by alpha-synuclein. ALS is typified by TDP-43. Huntington disease is typified by the huntingtin protein. And the idea was that these proteins, when they misfold and accumulate in the brain, damage neurons and cause the neurodegenerative disorders
Alector Inc at Bank of America Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers